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Erythrovirus B19 (B19V) is a member of the family Parvoviridae. Infection with B19V has been linked to a
variety of diseases including erythroid, thyroid, neurological and autoimmune diseases. Here we show
that infection of primary CD36+ cells with B19V coincides with downregulation of thyroid, retinoid, and
estrogen hormone receptors. In addition we show changes in expression of a variety of related
downstream signaling genes participating in cancer and cardiac-related diseases in B19V-infected
erythroid primary cells.
& 2013 Elsevier Inc. All rights reserved.Introduction
Erythrovirus B19 (B19V) belongs to the family Parvoviridae.
Discovered in 1975, B19V is now known to persist in many cells
and organs of the human body (Norja et al., 2008), however it has
been shown to replicate only in erythroid progenitor cells (EPCs;
Ozawa et al., 1986). The B19V genome contains a single promoter,
p6, that regulates expression of the major non-structural protein
NS1, two structural proteins VP1 and VP2, and two minor non-
structural proteins 11 kDa and 7.5 kDa (Heegaard and Brown,
2002).
NS1 plays a major role in the viral life cycle (Raab et al., 2002;
Astell et al., 1987). It trans-activates the p6 promoter and other
viral and cellular promoters such as HIV-LTR, IL-6, and TNF-α (Fu
et al., 2002; Sol et al., 1999) as well as induces apoptosis (Zhi et al.,
2006; Ozawa et al., 1988).
B19V causes a variety of diseases such as transient aplastic
crisis (Pattison et al., 1981), ﬁfth disease (Anderson et al., 1983),ll rights reserved.
iatry, College of Medicine,
Gainesville, FL 32610, USA.
ich),polyarthritis (Kerr, 2000), thrombocytopenia (Osaki et al., 1999),
non-immune hydrops fetalis (Levy et al., 1997), and myocarditis
(Dettmeyer et al., 2003). It is associated with multiple brain
disorders (Barah et al., 2003) and autoimmune diseases
(Lehmann et al., 2003). Recently, B19V infection has been strongly
associated with Hashimoto's thyroiditis and thyroid cancer by our
laboratory and others (Adamson et al., 2011; Wang et al., 2008,
2010), but the molecular mechanism of interaction between B19V
and thyroid signaling is unknown. Interestingly, it has been shown
that NS1 of the related parvovirus, minute virus of mice (MVM),
upregulates the expression of thyroid hormone receptor alpha
(THRα; Vanacker et al., 1996). Thyroid hormone (T3) was also
shown to increase the cytotoxicity of MVM (Vanacker et al., 1993).
Here we demonstrated that B19V infection of CD36+ EPCs leads
to downregulation of THRα, and that NS1 is sufﬁcient to induce
this downregulation. We also showed that B19V infection mod-
ulates the expression of estrogen and retinoid receptors, as well as
a variety of related downstream signaling genes involved in cancer
and cardio-vascular pathways.Results
To understand the inﬂuence of B19V infection on THRα expres-
sion we utilized CD36+ EPCs. The cells were either mock infected
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after infection, and 48 hours post infection (hpi). THRαmRNA level
was assessed by a conventional RT-PCR utilizing THRα speciﬁc
primers. As shown in Fig. 1(a) infection with B19V led to down-
regulation of THRα mRNA.
In order to quantify the differences in mRNA expression, qRT-
PCR was performed using pre-designed TaqMans gene expression
assays for THRα and GAPDH (Applied Biosystems, Foster City, CA).
Fig. 1(b) shows that signiﬁcant downregulation of THRα expression
was observed in cells infected with B19V.
Next, we examined whether B19V NS1 expression is responsible
for the downregulation of THRα expression. Since primary cells are
difﬁcult to transfect we utilized the erythroleukemia cell line K562.
We constructed a plasmid expressing either NS1 or GFP (as a negative
control) driven by the B19V p6 promoter. Cells were collected at 6, 24,
and 48 hours post transfection (hpt), and total RNA and protein were
isolated. Fig. 2(b) shows a moderate decrease of THRα mRNA level inFig. 1. Inﬂuence of B19V on THRα expression in CD36+cells. (a) THRα mRNA level assess
B19V (+). GAPDH mRNA was used as a loading control. NS1 mRNA expression was ob
technical replicates)¼4, mock SD (standard deviation)¼0.071, B19V SD¼0.011. p (p val
Fig. 2. Inﬂuence of B19V NS1 on THRα expression in K562 (a, b) and N-thy-ori (c, d) cells.
control. (b) mRNA Level was assessed by qRT-PCR using total RNA from cells mock-tr
p¼0.006). (c) Protein level was assessed by western blot, and GAPDH was utilized as a lo
p6-NS1 (NS1); THRα mRNA level was assessed by qRT-PCR 48 hpi (n¼3, mock SD¼0.09cells expressing NS1 48 hpt. Fig. 2(a) demonstrates the similar result
on protein level, starting with 24 hpt.
In order to examine whether such an effect occurs only in the
erythroid system strictly or is a common property of NS1, we
decided to utilize immortalized normal thyroid cells N-thy-ori.
Fig. 2(c) shows the decrease of the THRα protein level in cells
expressing NS1. Interestingly in this case antibody was able to
detect two isoforms of THRα—THRα1 and THRα2.
In order to exclude the possibility of the observed effect being
due to overexpression of NS1, and to mimic more natural condi-
tions, we constructed a recombinant adeno-associated virus
serotype 2 expressing either GFP or NS1 under B19V p6 (rAAV2-
p6-GFP and rAAV2-p6-NS1). As can be seen in Fig. 2(d) the THRα
mRNA level is signiﬁcantly downregulated in cells infected with
rAAV-p6-NS1 compared to mock infection 48 hpi.
THRs belong to the superfamily of nuclear receptors (NRs). The
members of this superfamily control the expression of many genesed by RT-PCR using total RNA from CD36+cells mock infected () or infected with
served 48 hpi. (b) THRα mRNA levels assessed by qRT-PCR 48 hpi [n (number of
ue)¼0.001].
(a) Protein level was assessed by Western blot, and GAPDH was utilized as a loading
ansfected or transfected with NS1 48 hpt. (n¼3, mock SD¼0.108, NS1 SD¼0.101,
ading control. (d) Infection of N-thy-ori cells with rAAV2-p6-GFP (mock) or rAAV2-
2, NS1 SD¼0.123, p¼0.008).
Fig. 3. Inﬂuence of B19V infection on nuclear receptor expression in CD36+EPCs.
qRT-PCR showing the relative level of mRNA expression for ESR1 (n¼3, mock
SD¼0.152, B19 SD¼0.149, p¼0.0002) and for RXRA (n¼3, mock SD¼0.01, B19
SD¼0.291, p¼0.0268).
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et al., 2010). We wanted to examine whether any other members
of the nuclear receptor family are affected by B19V. For NR
proﬁling we conducted a PCR microarray study targeting 92
known NRs. The most affected genes were validated by single-
tube qRT-PCR analysis. We have shown that B19 infection of
CD36+ EPCs leads to downregulation of retinoid X receptor alpha
(RXRA, or RXRα) and estrogen receptor alpha (ESR1, or ERα)
(Fig. 3).
To further characterize the observed changes in expression we
transfected N-thy-ori cells with either GFP or GFP-tagged NS1
(GFP-NS1). Cells were ﬁxed 48 hpt and stained with antibodies
against ERα, RXRA or THRα. Staining with antibodies against ERα
did not produce any speciﬁc signal (data not shown), however it
aligned with our previous observations of not being able to detect
ERα mRNA in this cell line (data not shown). As can be seen in
Fig. 4, in GFP-transfected cells RXRA and THRα localize to the
nucleus (Fig. 4(a)–(c) and (g)–(i), respectively). In comparison, in
GFP-NS1 cells nuclear localizations of RXRA and THRα were
reduced (Fig. 4(d)–(f) and (j)–(l), respectively). Interestingly, under
higher magniﬁcation inclusions were observed in the nuclei of the
cells transfected with GFP-NS1 and stained with THRα. The yellow
inclusions represent possible interactions between GFP-NS1 and
THRα (Fig. 4m, gray arrows); green alone, or green and red in a
close proximity to each other represent possible accumulations of
GFP-NS1 and THRα alone (Fig. 4m, black arrows).
THRs are tumor suppressors. We wanted to determine whether
there are any downstream genes in the THR signaling pathway
that are affected by B19V-mediated downregulation of THRα and
therefore could contribute to cancerogenesis. We decided to
concentrate on P53, MDM2, mTOR, PPARG, Cyclin D1, and CDK4
as their expression was affected in mice lacking THR (Zhu et al.,
2010). We showed that the mRNA levels of PPARG and Cyclin D1
were signiﬁcantly altered in CD36+ EPCs infected with B19V
compared to the mock control (Fig. 5a). Interestingly, despite the
rest of the genes not being signiﬁcantly affected, the changes
followed the trend observed in the work of Zhu et al. (2010).
Like THR, PPARG is a known tumor suppressor (Teresi and
Waite, 2008). Overexpression of Cyclin D1 has been implicated in
the progression of a variety of tumors (Sherr, 1996). Both THR and
PPARG have been implicated in cardiac-related diseases as well
(Gomberg-Maitland and Frishman, 1998; Hamblin et al., 2009).
Therefore, next we sought to determine whether there are any
other affected genes involved in cancerogenesis or implicated in
cardiac malignancies in B19V-infected CD36+ EPCs. We conducted
two PCR assays targeting known tumor promoters and genes
participating in cardiogenesis. The most affected genes validatedby single-tube qRT-PCR analysis are shown in Fig. 6b. In particular
we demonstrated that infection of CD36+ EPCs with B19V leads to
changes in expression of CCND2 (Cyclin D2), BMP2 (bone mor-
phogenetic protein 2) and SMAD9 (mothers against decapenta-
plegic homolog 9).
Taken together, this study demonstrates that B19V infection
leads to downregulation of THRα isoform in CD36+ cells, and that
B19V NS1 is sufﬁcient in both erythroid and thyroid cells to
mediate this effect. In addition it has been shown that the
infection of CD36+ EPCs with B19V leads to downregulation of
two other members of the NR family—ESR1 encoding for estrogen
receptor α and RXRA encoding for retinoid X receptor α. Utilizing
immunoﬂuorescence we have conﬁrmed the results for RXRA and
THRα as well as showed the possible interaction between NS1 and
THRα proteins. We have demonstrated that B19V-mediated change
of THRα expression coincides with the downregulation of the
PPARG and upregulation of Cyclin D1. Finally we have shown that
B19V infection of CD36+EPCs leads to changes in expression of
other cancer- and cardiac-related genes such as CCND2, BMP2,
and SMAD9.Discussion
Our data demonstrate the opposite effect of what has been
observed in the case of the MVM where viral infection led to
upregulation of THR expression. This can suggest that despite
being in the same family these two viruses evolved different
mechanisms of pathogenicity. THR plays a crucial role in
erythropoiesis. For instance, THRα / mice exhibited a variety of
erythroid defects (Kendrick et al., 2008). Interestingly, it has been
shown that THR expression was absent in one of the most
aggressive types of human cancer, anaplastic thyroid carcinoma
(Crescenzi et al., 2003). RXRA is known to form heterodimers with
THRα to control gene expression (Berrodin et al., 1992; Bugge et al.,
1992). The level of RXRA expression has been shown to be
decreased in thyroid cancer compared to benign tissues
(Hoftijzer et al., 2009). Downregulation of THRα and RXRA by
B19V could lead to alteration in expression of THR/RXR regulated
genes as well as contribute to erythroid pathologies and thyroid
cancerogenesis. Indeed we have shown that infection of CD36
+EPCs with B19V leads to downregulation of PPARG expression,
which is a known suppressor of follicular thyroid carcinoma, and is
downregulated in mice lacking THR (Zhu et al., 2010). ERα has
been intensively studied in the context of breast cancer, but has
also been implicated in a variety of thyroid proliferative diseases
(Rajoria et al., 2012). The preliminary results suggest that B19V
NS1 interacts with THR (Fig. 4m). Interestingly, the THR auto-
induction via the THR protein and the promoter of its own gene
has been documented in the amphibian tissues undergoing
metamorphosis, as well as rodent astrocytes (Tata, 2000). It has
also been shown that the promoter of human THRβ contains two
thyroid hormone response elements (TREs) that were shown to be
able to form complexes with both THRα and THRβ proteins. While
there are no similar reports describing the promoter of THRα gene
the results of co-localization experiments may provide a possible
novel insight on the mechanism of the regulation of THRα
expression and may suggest the formation of the NS1-THRα
complex that is able to bind to THRα promoter in order to regulate
its transcriptional activity. However more studies are needed to
characterize such interaction. B19V NS1 was shown to increase
expression of a variety of proinﬂammatory cytokines including
interleukin 6 (IL-6; Mitchell, 2002; Moffatt et al., 1996). NF-κB and
a nuclear factor for IL-6 (NF-IL6) have been shown to activate IL-6
transcription (Matsusaka et al., 1993). It was demonstrated that ER
forms heterodimers with NF-κB and NF-IL6 that are unable to bind
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Therefore downregulation of ER by B19V can be one of the ways
for the virus to increase IL-6 levels and modulate inﬂammation.
We expanded the scope of our research by ﬁnding additional
genes implicated in cancer (Cyclin D1 and CCND2) and cardiac
diseases (BMP2 and SMAD9) that were modulated by B19V.
Interestingly, interconnections between CCND2, BMP2 and ERα
have been shown (Sunami et al., 2008; Yamamoto et al., 2002).
B19V has been associated with inﬂammatory diseases such as
myocarditis (Andréoletti et al., 2009) and cardiomyopathy
(Bultmann et al., 2005). B19V is known to modulate inﬂammationFig. 4. Immunoﬂuorescence analysis of RXRA and THRα expression in GFP and GFP-NS
(d) GFP-NS1 (green), (e) RXRA (red), (f) merge of (d) and (e); (g) GFP (green), (h) THRα (r
(k); (m) zoom up of l. Blue—DAPI. Bars, 20 μm.)through activation of the STAT3 pathway (Duechting et al., 2008).
Cardiac proteins BMP2 and SMAD9 belong to the TGF-β superfamily
and have been shown to interact with the STAT3 pathway
(Kawamura et al., 2000; Snyder et al., 2008), and therefore could
be mediators of B19V-associated myocardial inﬂammation.
To our knowledge this is the ﬁrst report on a possible
molecular association between parvovirus B19V and thyroid/
retinoid/estrogen signaling. Such interconnections could shed
light on B19V pathogenesis. More studies are needed to eluci-
date the possible mechanisms of NR and NR-related gene
modulation and the role of such changes in the variety of1 transfected N-thy-ori. (a) GFP (green), (b) RXRA (red), (c) merge of (a) and (b);
ed), (i) merge of (g) and (h); (j) GFP-NS1 (green), (k) THRα (red), (l) merge of (j) and
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associated with B19V infection.Materials and methods
Infection of CD36+ EPCs with B19V
2106 CD36+EPCs (StemCell Technologies, Vancouver,
Canada) were washed with StemSpan serum-free expansion
media (SFEM; StemCell Technologies). Infection was carried out
in complete media (StemSpan SFEM, 1X dilution of StemSpan
CC100 cocktail, and 5 units of erythropoietin per 1 ml of media).
A total of 10 ml of serum containing 1109 wild-type B19V
particles were used to infect 106 cells as described previously
(Wong et al., 2008). Cells were collected at 0 and 48 hpi.Fig. 5. Quantiﬁcation of RXRA and THRα immunoﬂuorescence signal.
(a) Fluorescence intensity of RXRA in GFP (black) or GFP-NS1 (gray) expressing
cells (n¼3, nnp¼0.0015). (b) Fluorescence intensity of THRα in GFP (black) or GFP-
NS1 (gray) expressing cells (n¼3, nnp¼0.0006).
Fig. 6. Inﬂuence of B19V infection of CD36+EPCs on gene expression. (a) mRNA level
SD¼0.089 nnnp¼0.0001; Cyclin D1: mock SD¼0.159 B19 SD¼0.0035, np¼0.0022; n¼3)
SD¼0.056 p¼0.0048) and cardiogenesis (BMP: mock SD¼0.162 B19 SD¼0.129, p¼0.00Construction of the clones, transfection, and western blot.
PCR ampliﬁed sequences of p6 and NS1 (or GFP for mock
transfection) were cloned together into the pcDNA3.1+ vector
(Invitrogen) as MluI-PstI and PstI-EcoRI fragments respectively.
Transfection of erythroleukemia-derived cell-line K562 and
immortalized normal thyroid cell-line N-thy-ori (ATCC, Manass,
VA) was carried out in a six-well format using X-tremegene HP
(Roche, Indianapolis, IN) according to manufacturer's protocol.
Cells were collected at 6, 24, and 48 hpt, and total protein was
isolated using cell extraction buffer (Invitrogen, Carlsbad, CA)
supplemented with protease inhibitor cocktail (Sigma, St. Louis,
MO). 40 mg of total protein were subjected to 4–12% SDS-PAGE,
transferred to nitrocellulose membrane and probed with mouse
monoclonal antibodies against human THRα1/α2 (MA1-4674,
Thermos Scientiﬁc, Waltham, MA).
Construction and puriﬁcation of rAAV
PCR ampliﬁed sequences of p6 and NS1 (or GFP) were cloned
together with p6 promoter into pdsAAV2 vector using Acc65I-MluI
restriction sites for p6, and MluI-HindIII or MluI-SacI sites for GPF
and NS1 respectively. Viruses were puriﬁed as previously
described (Auricchio et al., 2001). N-thy-ori cells were seeded in
six-well plates at a concentration of 300,000 cells per well in
complete RPMI media. Infection was performed in serum-free
RPMI media for 2 h at 37 1C.
RT-PCR, qRT-PCR and microarrays
Total RNA was isolated using a Qiagen RNeasy Micro
kit (Hilden, Germany). 500 ng of total RNA was used for cDNA
generation (Verso cDNA kit, Thermo Scientiﬁc, Waltham, MA) with
oligo-dT primers. RT-PCR was performed with primers for THRα
(forward: 5′-GGCCTGGGCGTAGTCTCCGA-3′ and reverse: 5′-CAG-
GCCCGAGCGGTCTGTTG-3′), NS1 (forward: 5′-TGCCCTCCACCCA-
GACCTCC-3′ and reverse: 5′-AGGCGCCTGGGGTGATGAGG-3′), and
GAPDH (forward: 5′-AGCCACATCGCTCAGACAC-3′ and reverse:
5′-GCCCAATACGACCAAATCC-3′) as a normalizing control. All
qRT-PCR related products were purchased from Applied Bioisys-
tems (Foster city, CA). qRT-PCR was performed using pre-designedof THRα-related genes accessed by qRT-PCR 48 hpi (PPARG: mock SD¼0.094 B19
. (b) mRNA level of genes involved in cancerogenesis (CCND2: mock SD¼0.154 B19
01; SMAD9: mock SD¼0.302 B19 SD¼0.101, p¼0.0004; n¼3).
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Expression analysis of p53, MDM2, mTOR, PPARG, Cyclin D1, CDK4,
CCND2, BMP2 and SMAD9 was carried out using SYBR green mix
with primers for p53 (forward 5′-TGCTCAAGACTGGCGCTAAA-3′ and
reverse 5′-CAGTCTGGCTGCCAATCCA-3′), for MDM2 (forward
5′-AGGAGATTTGTTTGGCGTGC-3′ and reverse 5′-TGAGTCCGATGATTCC
TGCTG-3′), for PPARG (forward 5′-GTGGCCGCAGAAATGACCA-3′ and
reverse 5′-TGGGAGTGGTCTTCCATTACG-3′), for mTOR (forward 5′-CGA
TGGCCAGGGATCTCTTC-3′ and reverse 5′-GGTCTGTGTGACTTCAGCGA-
3′), for Cyclin D1 (forward 5′-ATGCCAACCTCCTCAACGAC-3′ and
reverse 5′-CGCAGACCTCCAGCATCC -3′), for CDK4 (forward 5′-CTCTC
TAGCTTGCGGCCTG-3′ and reverse 5′-GGGAGACCCTCACGCCA-3′),
CCND2 (forward 5′-GCTGCTGGAGTGGGAACTGG-3′ and reverse
5′-AGACAGCTTCTCCCGCTGCT-3′), for BMP2 (forward 5′-GGACATTCGG
TCCTTGCGCC-3′ and reverse 5′-GGTCGACCTTTAGGAGACCGCA-3′), and
for SMAD9 (forward 5′-CTTTCCAGCAGCCTCCGTGC-3′ and reverse
5′-GGGGTGGTGTGTCAACTGAGTG-3′). Primers were designed to span
exon–exon junction. For microarray studies we utilized signature fast
96-well plates (Cat numbers: 4418753, 4414161, 4418779) to assess
the differences of gene expression in mock- and B19V-infected
CD36+cells. Both qRT-PCR and microarray plates were run using
Applied Biosystems 7500 Fast system (ICBR, Gainesville, FL) according
to the manufacturer's protocol. Obtained results were analyzed by
DataAssist v3.0 software.
Immunoﬂuorescence
N-thy-ori cells were plated on coverslips coated with poly-
L-lysine. Cells were transfected with plasmids expressing either
GFP or GFP-tagged NS1. 48 hpi cells were ﬁxed in 4% paraformal-
dehyde, treated with 0.4% TritonX-100 and stained with antibodies
against RXRA (Santa Cruz, sc-553) or THRα (Thermo Scientiﬁc,
PA5-32615). Pictures were taken using a Leica TCS SP2 AOBS
spectral laser scanning confocal microscope (CTAC UF) and ana-
lyzed using ImageJ 1.46 (NIH).
Statistical analysis
Statistical analysis for qPCR and immunoﬂuorescence was
performed using a GraphPad t-test calculator software. Differences
were considered signiﬁcant when p-value was less than 0.05.Acknowledgments
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